Focused on transformative treatment technologies in dermatology and oncology.
The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet currently unmet needs in the skincare market.
Notice of Annual General Meeting 2024 and Posting of Annual Report and Accounts
Proactive TV Interview: Tim McCarthy - Increased Commercial Order and Analyst Research Note
Incanthera’s Skin+CELL rollout underpins ‘bright outlook’ for dermatology group